EGFR-sensitive mutated non-small cell lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Shanghai Pudong Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with stage I-III non-squamous NSCLC confirmed by histology or cytology (according to the 9th edition of the AJCC lung Cancer staging criteria). 2. Tumor tissue samples or blood samples have been confirmed by local laboratory tests to have EGFR-sensitive mutations (including EGFR19del/ 21L858R, which can exist alone or coexist with other EGFR site mutations). If the tumor tissue is inaccessible or the patient does not undergo tissue biopsy, a blood sample can be sent for testing. 3. Have received local ablation treatment and completed at least one imaging follow-up after treatment
Exclusion criteria
Exclusion criteria: In addition to NSCLC, another malignant disease has been diagnosed within the past five years (excluding completely resected basal cell carcinoma, carcinoma in situ of the bladder, and carcinoma in situ of the cervix). 2. There are contraindications for ablation (including but not limited to) a. Individuals with severe bleeding tendencies and coagulation disorders that cannot be corrected in the short term (prothrombin time >18 seconds, prothrombin activity 38.5 ?; d. Those with severe anemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in the short term; e. Anticoagulant therapy and/or antiplatelet drugs (except for new oral anticoagulant drugs such as dabigatran and rivaroxaban) were discontinued for no more than 5 to 7 days before ablation; f. Patients with implanted cardiac pacemakers. 3. Those who are deemed unsuitable for inclusion by the doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year event-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local Control Rate, LCR; | — |
Countries
China
Contacts
Public ContactLi Maoquan
Shanghai Pudong Hospital
Outcome results
None listed